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Abstract: 
Plasma C- reactive protein (CRP) has been proposed to be a strong independent predictor for 
cardiovascular disease. This circulating form of CRP (native CRP or nCRP) is well described. 
Recently, the existence of a conformationally distinct isoform of CRP (modified CRP or mCRP) 
has been reported. The relevance of each CRP isoform to atherosclerotic disease is unknown. 
The purpose of this study was to examine the natural expression of CRP in undifferentiated, 
differentiated, and stimulated macrophages, cells known to contribute to atherogenesis in vivo, 
and to determine whether transcribed CRP was expressed as nCRP or mCRP. Macrophages were 
generated from U937 monocytes using phorbol 12-myristate 13-acetate. Differentiated macro-
phages were further stimulated with lipopolysaccharides (LPS). In undifferentiated, 
differentiated, and stimulated cells, CRP expression was assessed by reverse transcription–
polymerase chain reaction, and CRP protein production was measured by fluorescence 
microscopy and flow cytometry (cellular CRP) or high-sensitivity enzyme-linked 
immunosorbent assay (secreted CRP). CRP transcript was minimally expressed in undifferenti-
ated cells. Expression increased markedly in macrophages during differentiation and was not 
affected by LPS at 24 hrs. Cellular CRP protein increased in a time-dependent manner after LPS 
stimulation, and this induction was mediated via interleukin (IL)-6 and IL-1p. A small amount of 
secreted CRP was detected in the media of differentiated cells, but it was not significantly 
increased after LPS stimulation. Using specific monoclonal antibodies, our data indicate that 
cellular CRP is directly translated as the mCRP rather than the nCRP isomer. These results 
indicate that U937-derived macrophages are a good cell model to further study the production of 
mCRP under conditions relevant for the atherogenic process. Exp Biol Med 230:762–770, 2005 
 
Article: 
Seven decades after its discovery, the acute-phase protein C-reactive protein (CRP) has emerged 
as a strong predictor for cardiovascular disease. These observations have accumulated as highly 
sensitive assays for the measurement of previously undetectable concentrations of circulating 
CRP became commercially available. Hence, low concentrations of CRP are sometimes denoted 
as high-sensitivity CRP (hs-CRP) to indicate the use of such assays. Recent studies conducted in 
healthy men and women indicate that plasma CRP concentrations as low as 1–3 gg/ml may 
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indicate an increased risk for future cardiovascular incidents (1–3). Therefore, hs-CRP was 
endorsed by the Centers for Disease Control and Prevention and by the American Heart 
Association for use in conjunction with a plasma lipid profile as part of global risk prediction for 
heart disease (4). Accumulating data indicate that CRP is not only a marker, but also an active 
player in the development of cardiovascular pathology (5). The latter aspect refers mainly to the 
association between CRP and processes of inflammation and the suggestion that it may modulate 
the low-grade inflammation that underlies atherogenesis. CRP has been reported to have both 
pro- and anti-inflammatory properties, so its exact role in the development of atherosclerosis 
remains an area of intense study. 
 
As an acute phase protein, CRP plasma levels are known to increase from —1 gg/ml to over 500 
gg/ml within 24–72 hrs of severe tissue-damaging events such as those caused by trauma, 
progressive cancer, acute myocardial infarction, and bacterial sepsis (6). Hence, the 
comparatively low levels of CRP qualified as predictive of heart disease require alternative 
thinking with regard to their possible biological relevance in early-stage disease. The widely held 
dogma is that CRP is produced exclusively by the liver (7), from which it is secreted into the 
circulation. Furthermore, any CRP found associated with distant tissue sites is perceived to 
originate from this circulating plasma pool. With the development of polymerase chain reaction 
(PCR) technology, however, it is now apparent that CRP transcript is expressed in various 
extrahepatic cells, including cells found in and around blood vessels (8–14). Few reports have 
characterized the translated product of the CRP transcript. In light of the evolving understanding 
that the different isoforms of CRP have distinct bioactivities, it is important to understand the 
nature of the synthesized CRP. To date, two CRP isomers have been described, namely native 
CRP (nCRP) and modified CRP (mCRP). Native CRP is composed of five non–covalently 
bound globular subunits arranged as a cyclic annular disc. This isoform is known to be 
synthesized by hepatocytes and represents the circulating form of the protein. Native CRP binds 
to substrates displaying phosphorylcholine moieties in a calcium-dependent manner, and when 
complexed, nCRP can activate the Complement system. Modified CRP is a conformationally 
distinct, poorly soluble isoform associated with a free CRP subunit. It can be irreversibly 
generated from nCRP by nonproteolytic dissociation of the pentameric disc. The 
―modified‖ subunits tend to self-aggregate (15–17). Antigens cross-reactive with its distinctive 
antigenicity have been found in various tissues or cells or as a membrane- bound protein (i.e., 
tissue-based CRP) (8, 12, 18–21). In vitro, mCRP can be produced from nCRP by exposing 
nCRP to heat, urea, or acidic conditions, generally in the absence of calcium ions (17). Modified 
CRP can also spontaneously form from nCRP with storage. When the human CRP subunit gene 
was first isolated and expressed in Xenopus oocytes, the pre-CRP translation product containing 
an 18–amino acid leader sequence and expressed mCRP antigenic epitopes in preference to 
nCRP epitopes (22). 
 
In vitro studies have reported that CRP is a proatherogenic protein with chemoattractant 
properties toward monocytes (23). In addition, CRP stimulated the expression of adhesion 
molecules (24), facilitated the uptake of low density lipoprotein in the intima, thereby promoting 
foam- cell formation (25); activated the complement system (26); and impeded vasorelaxation 
(27). None of these studies differentiated the possible effects of nCRP from those of mCRP. In 
vitro studies directly addressing the distinct isoforms of CRP have reported that mCRP displays 
proinflammatory effects on neutrophils, endothelial cells, and platelets, while nCRP displays 
anti-inflammatory activities (28–31). These studies used exogenously added CRP and did not 
address the existence and possible role of naturally occurring protein. The effects of cell-
expressed CRP may be significant in unraveling the role of CRP in coronary vessel disease. 
 
The present study was initiated to determine whether CRP was expressed by cells such as 
macrophages that are present in the atherosclerotic milieu and whether pro- inflammatory stimuli 
such as lipopolysaccharides (LPS) could affect CRP expression. This study also directly 
addressed, for the first time, the isoforms of CRP produced by the U937-derived macrophages. 
 
MATERIALS AND METHODS 
Cell Culture.  
U937 human promonocytic cells (CRL1593.2; American Type Culture Collection, Manassas, 
VA) were grown in RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO) supplemented 
with 10% fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin/streptomycin, and 0.2% 
amphotericin B. Cells within three passages were differentiated into macrophages by stimulation 
with 10 nM phorbol 12-myristate 13-acetate (PMA) for 72 hrs. Differentiation was determined 
by increased cell attachment to the flasks and by changes in cell morphology, namely larger cell 
size, increased membrane ruffles, and small nucleus and large cytoplasm filled with vacuoles. In 
some experiments, the CRP production was assessed in response to LPS stimulation (1 µg/ml 
LPS for 24–72 hrs). Optimization studies were also conducted to ensure that the production of 
CRP in PMA-differentiated macrophages was not modified when cells were maintained in media 
without LPS for 24–72 hrs post-differentiation (data not shown). 
Antibodies and Chemicals.  
Several monoclonal mouse anti-human CRP antibodies (mAbs) were used as primary antibodies 
in indirect immunofluorescence procedures (Table 1). Clone-8 CRP mAb was purchased from 
Sigma Chemical. According to the manufacturer, this antibody recognizes both native and 
denatured CRP isoforms. The 8D8, 8C10, and 9C9 mAbs were provided by Dr. L. Potempa and 
prepared as previously described (32). The 8D8 mAb specifically reacts with nCRP, and the 
8C10 and 9C9 mAbs react with mCRP. The 9C9 mAb recognizes the C-terminal octapeptide of 
the CRP subunit, which is buried within the intersubunit contact regions of the nCRP structure 
and is expressed when the subunits are dissociated. The 8C10 mAb recognizes an epitope on the 
N- terminal 16-kDa fragment of the mCRP isoforms (33). This epitope is conformationally 
sensitive, requiring the single intrachain disulfide bond of the CRP subunit, in the mCRP 
isoform, to be intact. 
 
The secondary antibody used in indirect immunofluorescence procedures was a FITC-F(ab')2 
goat anti-mouse IgG (Jackson Immunoresearch Laboratories, Inc., West Grove, PA). In 
fluorescence microscopy studies, this tag gave a green signal for positive staining when captured 
with the fluorescein filter. For flow cytometry studies, the wavelength emission of this 
fluorochrome required the FL1 channel for data acquisition (excitation wavelength: 488 nm; 
emission wavelength: 525 nm). 
 
For neutralization studies, monoclonal mouse antihuman interleukin (IL)-10 and IL-6 antibodies 
(R&D Systems, Minneapolis, MN) were used. These mAbs are known to efficiently neutralize 
circulating IL-1β and IL-6 (34). All the chemicals were purchased from Sigma Chemical, unless 
stated otherwise. 
RNA Isolation.  
RNA isolation was performed using the RNeasy mini-kit (Qiagen, Inc., Valencia, CA), accord-
ing to manufacturer’s instructions. 
 
Reverse Transcription (RT)–PCR.  
RT-PCR was performed using the One-Step RT-PCR kit (Qiagen) and the following CRP 
primers (Invitrogen Life Technologies, Carlsbad, CA): sense: TCGTATGCCACCAAGAGACA  
AGACA; antisense: AACACTTCGCCTTGCACTTCATACT (11); 18S ribosomal RNA 
(Ambion, Austin, TX) provided an internal standard. The 100–base pair (bp) ladder was purchased 
from New England BioLabs (Beverly, MA). Reactions were carried out using 1  gg RNA. 
PCR  amplification was conducted for 30 secs at 94°C, 30 secs at 55°C, and 1 min at 72°C. The 
reaction was optimized for 35 cycles. Amplified DNA was separated on a 1.5% agarose gel 
containing 1 pl ethidium bromide (10 mg/ml) and was quantified using a Kodak imaging station 
440 CF (Rochester, NY). The amplification of genomic DNA was  excluded by running 
samples for which the RT step had been omitted. 
 
Immunofluorescence Studies.  
The presence of the protein in macrophages was determined using fluorescence microscopy and 
flow cytometry in both live and fixed cells. Live cells were used to identify membrane- 
expressed CRP, while fixed cells were screened for total cellular CRP. In addition, live cells were 
permeabilized with saponin for a closer analysis of CRP intracellular distribution after the 
extraction of soluble cytoplasmic components. Primary antibodies were used in a dilution of 1 to 
500 (purified clone CRP-8 mAb) or 1 to 20 (murine hybridoma culture supernatants of 8D8, 8C10, 
and 9C9 mAbs), and the secondary FITC-conjugated antibody was used in a dilution of 1 to 400. 
For immunostaining of live cells, cells were grown on poly–L-lysine–coated slides and were 
then  successively incubated with primary and secondary antibodies diluted in blocking buffer 
(3% bovine serum albumin/phosphate-buffered saline [BSA/PBS]). Cells were incubated with the 
primary antibody overnight, washed with blocking solution twice, and then exposed to the secondary 
antibody for 1.5 hrs in the dark. All the steps were  performed at 4°C. Immunostaining of 
fixed cells was  performed in macrophages that had been attached onto  poly–L-lysine–coated 
slides after PMA-induced differentiation and, in some experiments, in undifferentiated U937  
monocytes that had been attached to the slides by  cytospinning. Briefly, 1 X 105 cells were 
loaded onto slides in Cytospin Chambers (StatSpin, Norwood, MA) and were cytospun in a 
Cytofuge (StatSpin) for 4 mins at 850 rpm (40 g). Once cells were adherent to the slides, they 
were fixed with 3.7% formaldehyde, washed with 2% glycine/3%  BSA/PBS to quench excess 
reactive aldehydes, and then permeabilized with 0.1% saponin. Cells were blocked with 3% 
BSA/PBS–0.1% saponin for 30 mins at 4°C. All the antibodies were diluted in the blocking 
solution. Cells were incubated with the primary antibody overnight at 4°C, washed with blocking 
solution twice, and then exposed to the secondary antibody for 1.5 hrs at room temperature in  the 
dark. For both live and fixed cells, after the incubation with the secondary antibody, slides 
were thoroughly washed, mounted, and then analyzed using fluorescence  microscopy. For live 
cells permeabilized with saponin, the same steps were taken as for the staining of live cells, but  
0.1 % saponin was included in all the buffers, as described in the staining of fixed cells. After 
adequate washing, images were captured with a SPOT digital camera mounted on an Olympus 
BX60 fluorescence microscope. 
 
For flow cytometry, cells grown in six-well plates were detached using a rubber policeman and 
collected in polystyrene tubes in ice-cold PBS containing 0.1% sodium azide. The staining 
procedures for fixed and live cells were performed in a manner similar manner to that described 
above. Cells were analyzed using a Becton-Dickinson FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA). Negative (unstained cells) and isotype (cells incubated only with the 
secondary antibody) controls were included for each sample. The cell population used for 
acquiring data was gated to exclude any debris that would increase the nonspecific signal. 
Quantitative data were collected from 10,000 cells and were reported as mean fluorescence 
intensity (MFI). 
 
Enzyme-Linked Immunosorbent Assay (ELI- SA).  
Soluble CRP secreted by macrophages was measured in the supernatant using a high-sensitivity 
assay (hs-ELISA; Diagnostic Systems Laboratories, Inc., Webster, TX). Prior to the assay the 
supernatant was concentrated 5-fold using Vivaspin 6 concentrating devices (Vivascience, 
Hannover, Germany). 
 
Statistical Analyses.  
To ensure reproducibility, experiments were conducted in duplicate and were conducted at least 
three times. Statistical analyses (one-way analysis of variance [ANOVA], Student’s t test) were 
performed on data gathered from three experiments. The level of significance was set at the 0.05 
level. 
 
RESULTS 
CRP Transcript.  
The expression of CRP was assessed by RT-PCR in U937 monocytes (undifferentiated 
monocytes), in U937 monocytes differentiated to macrophages using PMA (PMA-differentiated 
macrophages), and 
 
Figure 1. The expression of CRP in U937-derived macrophages. U937 cells (5 x 10
6
) were seeded in 100-mm cell 
culture dishes and differentiated into macrophages with 10 nM PMA for 72 hrs in the presence of RPMI medium 
containing 10% FBS. When the differentiation was terminated, cells were washed with PBS and then incubated in 
fresh media alone or in media containing 1 µg/ml LPS for another 24 hrs. After 24 hrs, cells were collected by 
scraping, and RT-PCR was performed on RNA isolated from U937 undifferentiated monocytes (Lane 2, U), PMA-
differentiated macrophages (Lane 3, PMA), and LPS-stimulated macrophages (Lane 4, LPS). Lane 1 represents the 
100-bp DNA ladder marker. 18S rRNA was used as an internal control. The results presented are representative of 
triplicate experiments. 
 
in macrophages stimulated with 1 µg/ml LPS for 24 hrs (LPS-stimulated macrophages). CRP 
transcript (440 bp) was detected in similar amounts in macrophages before and after LPS 
stimulation, but was only minimally detected in undifferentiated U937 cells (Fig. 1). In two other 
experiments, no CRP expression was detected in undifferentiated U937 monocytes (data not 
shown). Collectively, these three experiments indicate increased gene expression of CRP in 
differentiated and stimulated U937-derived macrophages compared to undifferentiated U937 
monocytes, and they indicate that undifferentiated cells may express low levels of CRP 
transcript. 
 
CRP Protein.  
The presence of CRP protein was assessed in U937 undifferentiated monocytes (Fig. 2A) and in 
macrophages before (Fig. 2B) and after 24-hr stimulation with LPS (Fig. 2C). Fluorescence 
microscopy experiments were conducted in fixed cells using clone-8 CRP mAb. CRP protein 
was detected in very low amounts in U937 undifferentiated monocytes. Its production was 
significantly higher in differentiated macrophages and was not influenced by LPS stimulation. 
However, notable differences in cell morphology and in the amount and distribution of CRP 
were observed in response to LPS. For example, PMAdifferentiated macrophages prior to LPS 
stimulation were more round, with poorly developed filopodia, and they displayed homogeneous 
CRP staining, mainly in the perinuclear area. Conversely, LPS stimulation enhanced the cell 
spreading, polarization, and filopodia formation, changes that were accompanied by an increase 
in CRP, which showed a diffuse localization in the cytoplasm, sometimes with a tendency 
toward polarization. 
 
Subsequent experiments were conducted to quantify the production of CRP before and after an 
LPS challenge in a time-course study. Macrophages were stimulated with LPS for 24–72 hrs. 
Flow cytometry analysis was performed on fixed cells using the clone-8 CRP mAb. LPS-
stimulated macrophages showed a significant increase in CRP compared to unstimulated 
macrophages (Fig. 3). The amount of CRP produced in response to LPS stimulation at any time 
point was greater than that measured in unstimulated macrophages (P < 0.001). LPS-stimulated 
macrophages showed a time-dependent production of CRP, whereby the protein increased 60% 
from baseline in the first 24 hrs and then increased an additional 25% between 24 and 48 hrs (P < 
0.001). Between 48 and 72 hrs, there was no significant further increase in the production of 
CRP. 
 
To test the involvement of proinflammatory cytokines IL-10 and IL-6, which have been 
identified as regulators of hepatic production of CRP, a neutralization study was conducted using 
flow cytometry in fixed cells. CRP was detected using clone-8 CRP mAb. Anti–IL-10 and IL-6 
mAbs, which are known to neutralize these cytokines, were used at 50 µg/ml and were added to 
the media separately or in combination and simultaneously with LPS. The amount of CRP 
protein quantified after exposing macrophages to LPS for 72 hrs in the absence of neutralizing 
mAbs was assigned a relative value of 100%. In the presence of anti– IL-10 mAb, the relative 
level of CRP produced was decreased by 50%. In the presence of anti–IL-6 mAb, production of 
CRP was decreased by 78%. No synergistic or other effect on CRP synthesis was noted if both 
cytokines were neutralized at the same time by a combination of the two antibodies (Fig. 4). 
 
Secreted CRP was measured by hs-ELISA in the culture supernatant above plate-immobilized 
macrophages. Culture supernatants were concentrated 5-fold prior to detection. The baseline 
concentration of CRP measured in PMA-differentiated macrophages was 10 ng/ml. After 
stimulation with LPS for 72 hrs, CRP concentration increased slightly, but insignificantly, to 13 
ng/ml (data not shown). 
 
CRP Isoforms.  
Fluorescence microscopy experiments conducted in both live and fixed cells showed that LPS-
stimulated macrophages produced mCRP, but not nCRP (Fig. 5). In live cells, mCRP was 
specifically identified using the 9C9 mAb that recognizes the C-terminal octapeptide of the CRP 
subunit (Fig. 5A1). In these live cells, the 8C10 mAb, which recognizes an epitope expressed on 
the N-terminal 16-kDa fragment and is dependent on an intact intrachain disulfide bond of 
mCRP, showed no staining (Fig. 5A2). The 8D8 mAb, which is specifically reactive with nCRP, 
also showed no staining (Fig. 5A3). An intense fluorescence was found when using the clone-8 
CRP mAb (Fig. 5A4). 
 
In fixed cells (Fig. 5B), mCRP antigenicity identified by 9C9 mAb was strongly expressed (Fig. 
5B1), while nCRP antigenicity identified by 8D8 mAb was negative (Fig. 5B3). In fixed cells, 
anti-mCRP 8C10 mAb reacted 
 
Figure 2. The production of CRP in U937-derived macrophages. U937 cells were attached to poly–L-lysine glass 
slides by cytospinning and used for immunostaining of undifferentiated monocytes. Also, U937 cells were attached to 
poly–L-lysine glass slides after differentiation into macrophages using 10 nM PMA for 72 hrs in the presence of 
RPMI medium containing 10% FBS. Finally, differentiated cells were washed with PBS and then incubated in fresh 
media alone or in media containing 1 gg/ml LPS for another 24 hrs. After 24 hrs, these stimulated cells were prepared 
for immunostaining. CRP was identified in undifferentiated monocytes (Panel A) and in PMA-differentiated 
macrophages before (Panel B) and after (Panel C) LPS stimulation. Cells were fixed and immunostained as described 
in Methods. Clone-8 CRP mAb was used as primary antibody. Cells were analyzed using a fluorescence microscope 
with x100 and x40 magnifications. The results presented are representative of triplicate experiments. 
with the same general distribution pattern and intensity as anti-mCRP 9C9 mAb (Fig. 5B2). As 
with live cells, intense fluorescence was found using clone-8 CRP mAb, showing a staining 
pattern analogous to that observed with both antimCRP mAbs (Fig. 5B4). 
 
 
Figure 3. The effect of LPS on CRP production in U937-derived macrophages. U937 monocytes were seeded in six-
well plates and differentiated into macrophages with 10 nM PMA for 72 hrs in the presence of RPMI medium 
containing 10% FBS. When the differentiation was terminated, cells were washed with PBS and then incubated in 
fresh media alone or in media containing 1 lg/ml LPS for another 24–72 hrs. Indirect staining was performed using 
clone-8 CRP as primary antibody and FITC-F(ab’)2 goat anti-mouse IgG as secondary antibody. Cells were collected 
and analyzed by flow cytometry, and data were reported as mean fluorescence intensity (MFI). Values represent 
mean ± SEM. Results from at least three experiments were analyzed using one-way ANOVA. Letters above bars 
designate significant differences among various time points (P < 0.001). 
 
To further understand the differential reactivity of 8C10 mAb in live and fixed cells, we studied 
the presence of CRP isoforms in cells permeabilized with saponin but not fixed, since fixation 
procedures might interfere with epitope recognition by specific antibodies. The recognition 
pattern of mAbs toward CRP was similar to that found in live cells, in that mCRP was detected 
by 9C9 (Fig. 5C1) and clone-8 CRP mAbs (Fig. 5C4) but not by 8C10 mAb (Fig. 5C2). Native 
CRP was absent, as shown by the lack of staining obtained using the 8138 mAb (Fig. 5C3). 
 
Flow cytometry studies supported these findings (data not shown). In live cells, mCRP staining 
was detected using either 9C9 or clone-8 CRP mAbs, but not 8C10 mAb. No nCRP was found 
with the anti-nCRP 8138 mAb. In fixed cells, CRP staining was detected using anti-mCRP 9C9 
and 8C10 mAbs as well as with clone-8 CRP mAb, but not with anti-nCRP 8138 mAb. 
 
DISCUSSION 
Although the presence of CRP in atherosclerotic tissue has been clearly established, it is 
unknown whether CRP is deposited at these sites from the blood or is produced locally by cells 
involved in the development or control of the atherosclerotic lesion. What is also unknown, and 
which is relevant to truly understanding the bioactivities of CRP, is whether CRP protein that is 
found at atherosclerotic sites is present as the native-pentameric isoform, or as the distinct 
 
Figure 4. Cytokine-mediated CRP production in LPS-stimulated macrophages. U937 monocytes were seeded in six-
well plates and differentiated into macrophages with 10 nM PMA for 72 hrs in the presence of RPMI medium 
containing 10% FBS. When the differentiation was terminated, cells were washed with PBS and then stimulated with 
1 gg/ml LPS for 72 hrs. Anti–IL-1R and IL-6 mAbs (50 gg/ml) were added to the media separately or in combination and 
simultaneously with LPS. Indirect staining was performed using clone-8 CRP as primary antibody and FITC-
F(ab’)2 goat anti-mouse IgG as secondary antibody. Cells were collected and analyzed by flow cytometry. The 
histogram presented is representative of two different experiments. 
 
mCRP isoform. Yasojima et al. (11) have reported that CRP transcript and protein are expressed 
in macrophages and smooth muscle-like cells in or near atherosclerotic plaques. Supporting 
evidence also comes from Kobayashi et al. (14), who reported production of CRP in human 
coronary smooth muscle cells. Although the presence of CRP in the arterial wall is well 
established, the precise identification of the CRP isoform being expressed is unknown. Since a 
tissue-based form of CRP antigenically cross-reactive with mCRP has been reported to be 
expressed in normal blood vessel intima (8), its relevance to the development of atherosclerotic 
plaques requires clarification. 
The present study addresses the aforementioned questions using a cell model relevant for the 
atherogenic process in vivo, namely monocyte-derived macrophages. The expression of CRP 
transcript was minimally detected in undifferentiated monocytes and was clearly upregulated in 
PMA-differentiated macrophages. Further stimulation of PMA-differentiated macrophages with 
LPS for 24 hrs did not increase the amount of CRP transcript. The fact that the expression of 
CRP is strongly induced upon differentiation may reflect a role for CRP during the cytoskeletal 
rearrangement that occurs during monocyte transition to macrophages, as has been previously 
suggested (35, 36). 
 
Figure 5. Identification of CRP isoforms in LPS-stimulated macrophages. U937 monocytes were seeded onto poly–
L-lysine glass slides and differentiated into macrophages with 10 nM PMA for 72 hrs in the presence of RPMI 
medium containing 10% FBS. When the differentiation was terminated, cells were washed with PBS and then further 
stimulated with 1 gg/ml LPS for 72 hrs. CRP was identified in live (Panel A), fixed (Panel B), or live cells 
permeabilized with 0.1% saponin (Panel C). The primary antibodies used were anti-Mcrp 9C9 mAb (1), anti-mCRP 
8C10 mAb (2), anti-nCRP 8D8 (3), and Sigma clone-8 CRP mAb (4). Cells were analyzed using a fluorescence 
microscopy with a x40 magnification. The results presented are representative of triplicate experiments. 
 
 
Further investigation of the effect of LPS on the production of CRP protein showed that LPS 
time-dependently increased the production of CRP, peaking at 48 hrs. After 24 hrs of LPS 
stimulation, macrophages had a significantly higher amount of CRP protein compared with 
unstimulated, differentiated macrophages. 
 
Besides the significant increase in the amount of CRP protein produced in response to a 24-hr 
LPS stimulation, there were also changes in macrophage morphology and in the amount and 
distribution of CRP protein, as detected by fluorescence microscopy. These aspects indicate a 
state of activity induced in macrophages by an LPS challenge. 
 
Since there was no concurrent increase in the level of CRP mRNA level detected in PMA-
differentiated macrophages in the presence or absence of LPS stimulation, these results indicate 
that LPS modulates CRP synthesis at the translational rather than the transcriptional level. It has 
been previously suggested that differentiation is an inducer of gene transcription, but an 
additional stimulus is needed to promote translation (37). It is possible that in our study the 
presence of LPS was needed to efficiently promote the translation of CRP mRNA induced upon 
differentiation. 
 
The LPS-induced production of nCRP has been studied mainly in hepatocytes and has been 
shown to be mediated by two proinflammatory cytokines, IL-10 and IL-6, which synergistically 
stimulate CRP (38, 39). Only recently has it been shown that CRP can be produced at 
extrahepatic sites in response to proinflammatory stimuli. Specifically, Jabs et al. (12) reported 
that in renal cortical epithelial cells, IL-6 is a better inducer of CRP transcript than is IL-10 and 
that conditioned media obtained from LPS-stimulated peripheral blood mononuclear cells led to 
a 1000-fold increase in the expression of this gene. Calabro et al. (40) found that the level of 
CRP transcript and concentration of CRP released from human coronary smooth muscle cells 
was greater in response to IL-6 than in response to IL-1 0. The combination of the two cytokines 
and the LPS proved to be the strongest stimulants of CRP in these cells. Our results confirmed 
that using monocyte-derived macrophages, LPS-induced synthesis of CRP protein does involve 
these two cytokines, with IL-6 being the predominant cofactor. We were unable to demonstrate, 
however, an additive effect of these two cytokines on the CRP synthesis response. 
 
In the present study, although LPS induced a time- dependent increase in the production of cell-
associated CRP, the soluble CRP measured in macrophage supernatant was minimal and was not 
significantly affected by LPS stimulation. If extrapolated to in vivo conditions, this result 
indicates that it is unlikely that CRP released from macrophages contributes significantly to the 
overall plasma concentration of this protein. 
 
Although there are other studies that reported the presence of small amounts of CRP in the 
supernatant of nonhepatic cells (12, 40, 41), the identification of specific isoforms of CRP 
released from cells has not been addressed. To present, only Jabs et al. (12) reported the presence 
of denatured CRP in the supernatant of renal cortical tubular epithelial cells. In the present study, 
the ELISA kit used to measure soluble CRP did not allow a specification of CRP isoforms 
secreted in the media. 
 
The production of cell-expressed CRP protein was investigated using highly characterized 
monoclonal antibodies. In the present study we showed that LPS-stimulated macrophages 
produce mCRP rather than nCRP, as the modified isoform was detected by the 9C9 mAb and the 
presence of native isoform was excluded by using the 8D8 mAb. The results obtained using 
Sigma clone-8 CRP mAb were similar to those obtained using the 9C9 mAb raised specifically 
against the mCRP isoform. These observations are in agreement with findings previously 
reported by others, in that clone-8 CRP mAb recognizes mCRP and not nCRP (12, 13, 42). 
 
A conspicuous difference was found between live and fixed cells with regard to the way they 
stained in the presence of the 9C9 and 8C10 antibodies. In live cells, the 9C9 mAb raised against 
the C-terminal of mCRP gave a positive staining in live cells, whereas the 8C10 mAb raised 
against the N-terminal of mCRP was negative. In fixed cells, both mAbs gave a diffuse positive 
staining. These results indicate that the C-terminal epitope is exposed on the outer side of the cell 
membrane, while the N-terminal epitope is masked or embedded in the membrane. We 
hypothesized that this epitope became available to bind to its antibody as a consequence of 
fixation/permeabilization. To test this possibility, we performed fluorescence microscopy studies 
in live cells permeabilized with saponin, but not fixed. We found that the 9C9 but not the 8C10 
mAbs detected mCRP, indicating that fixation is necessary to gain access to the N- terminal 
epitope recognized by the 8C10 mAb. This result indicates that binding of 8C10 mAb to its 
epitope requires not only the access of the antibody to the inner part of the membrane but 
probably a conformational change that is induced by fixation (e.g., cross-linking). The 8C10 
mAb is a less-robust antibody compared to 9C9 mAb, and its reactivity depends on the integrity 
of the intrachain disulfide bond of mCRP. Since the extent to which experimental procedures 
affected this structure is not known, the results obtained using the 8C10 mAb should be 
interpreted with caution. Further exploration of this aspect is needed. 
 
Another aspect captured when comparing the immunostaining of live and live permeabilized 
cells was related to changes in the disposition of mCRP detected with the 9C9 and clone-8 CRP 
mAbs. The staining pattern obtained with the 9C9 mAb showed a more intense cytoplasmic 
mCRP, but still retained an annular disposition evoked by the staining of live cells in the absence 
of permeabilization. Conversely, clone-8 CRP mAb showed a total change in mCRP disposition, 
in that a strong signal was present in the cytoplasm of permeabilized cells, and no annular pattern 
was conserved. Permeabilization results in the extraction of soluble cytoplasmic components but 
leaves intact the microtubules and intermediate filaments. In permeabilized cells, CRP deposits 
were identified as granular deposits with a degree of polarization, probably associated with the 
formation of intermediate filaments and the anchorage of cells to the plate. 
 
At this point, our data demonstrate that mCRP is present in the cytoplasm of monocyte-derived 
macrophages, and these findings are in agreement with reports from other studies that identified 
mCRP antigens intracellularly (22, 42). However, the immunofluorescence data are insufficient 
to enable a clear localization of the mCRP with respect to the cell membrane. 
 
In summary, our findings show that CRP is expressed by monocyte-derived macrophages and 
that it is produced as the modified rather than the native isomer. In our cell model, mCRP was 
induced during the differentiation process and was further increased in response to LPS 
stimulation. 
Since mCRP is reported to have proinflammatory activities, it is of interest to speculate whether 
natural expression of this protein contributes to the low-grade inflammation that is associated 
with atherogenesis. In any respect, CRP constitutes an ideal target for pharmacologic 
interventions directed toward the prevention and treatment of cardiovascular disease. Our 
ultimate aims were to assess the presence of CRP and to describe its modulation in response to 
inflammatory stimuli and to characterize the forms of CRP in a cell model relevant for 
atherosclerosis. The importance of having such a cell model resides in the fact that further 
mechanistic studies could be easily performed to fully understand the structure and functions of 
CRP. 
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